Penn Center for Innovation

Working with PCI

PCI will walk you through the steps to partner with Penn researchers, invest in their discoveries, and license their creations

Leading Innovation at Penn

Penn has world-class scientific laboratory facilities. Many of them are available for third-party use

Browse Penn-owned technologies available for licensing

At the core of any new industry venture is innovative technology — whatever type you’re looking for, PCI has the details

PCI -Affiliated Startups

The following startups were spun out from technology invented at the University of Pennsylvania.

Additional PCI Ventures-affiliated startups can also be found here.

View the list of Penn startups currently seeking funding here.


Cantius Therapeutics

Cantius Therapeutics, LLC has a unique and well-placed strategy to treat cachexia and block nausea/emesis. Our GRASP technology utilizes small peptides that penetrate the brainstem to antagonize the GFRAL-Ret receptor complex. This receptor complex, expressed exclusively in the brainstem, was recently established as the sole mediator of GDF15 (MIC-1) signaling, a cytokine critical in disease-induced cachexia, anorexia, and emetic behaviors from cancer, chemotherapy, and pregnancy-induced morning sickness.



Looking for: Partnerships, Seed Investment, Management

Contact: Neal Lemon. Reference Dockets # 19-8758


Hypknowledge LLC

Hypknowledge is unique in that it is not intended for individuals with sleep disorders or sleep complaints. Instead, its functionality is geared toward allowing average to good sleepers to achieve better sleep.

This app provides data-driven insights and recommendations to help people get their most, best sleep. It was developed to allow people to make better use of the data that they obtain from tracking their sleep (whether the data is obtained by sleep diaries, wearable devices, or some combination).

Although some individuals may be content to simply obtain sleep information as an end goal, we believe that this wealth of information may also be used for the purpose determining if each individual can achieve, and benefit from, more sleep. We hope you will find it useful. Sleep well.


Documents: Overview

Looking for: Partnerships, Seed Investment, Management

Contact: Neal Lemon. Reference Dockets # 19-8987, 19-9031, 20-9161



Instanosis Inc. focuses on commercialization of an innovative and broadly-applicable point-of-care platform to detect ultra-low concentrations of disease biomarkers, with the lead application being an ultrasensitive and low-cost COVID antigen test.

The technology is based on proprietary technology developed out of the Founder’s laboratory at Penn. This platform has many applications in Infectious Diseases, Cardiology, Neurology and other disease areas, where rapid, convenient and ultra-sensitive biomarker detection is crucial for disease detection and treatment.

Founder: Dr. Ping Wang


Looking for: Partnerships, Seed Investment, Management

Contact: Neal Lemon Reference Dockets # 18-8594, 20-9363




MyoArete is developing newly identified utrophin upregulation therapies that treat all Duchenne Muscular Dystrophy patients.

Utrophin when upregulated, functionally substitutes for the missing dystrophin and has been validated in preclinical studies, but not as yet translated to patients. MyoArete will leverage newly described platforms developed by the founder’s laboratory at Penn that target post-transcriptional repression mechanisms to harness utrophin upregulation-based treatments.

Utrophin upregulation treatments are predicted to improve function, slow disease progression, and increase lifespan in all DMD patients, regardless of mutation status. In addition, toxicity due to immune reactions or rejection is not expected with MyoArete’s approach of increasing the expression of utrophin, a protein that is already present in muscle. Notably, no toxicities have been noted with utrophin upregulation in animal studies. The platform and products are protected by patents and PCT filings.

Founder: Tejvir S. Khurana, MD, PhD. Email


Looking for: Partnerships and Seed Investment

Investor Relations:  Neal Lemon, PhD, MBA   Reference Dockets # 21-9570, 20-9100, 18-8707, 18-8703



There are 230 million surgeries performed per year worldwide. Surgical experience is the primary factor dictating outcome of each operation. However, surgical experience is not quantifiable, not accessible as a data source, and not easily distributable between users. This leads to variability in outcomes, complications, inefficiency, and high costs in surgical care delivery.

TAIRIS is developing an artificial intelligence (AI) platform designed to quantify and learn from surgical experience, then customize and distribute tailored information back to surgeons in real-time. TAIRIS Artificial Operative Assistant (AOA), is an Augmented Intelligence system built on a custom deep learning framework with a generalizable and scalable infrastructure. The AOA processes live surgery feeds and presents intelligent guidance and predictive analytics back to surgeons in real-time.


Documents: Pitch Deck

Looking for: Partnerships and Seed Investment

Contact: Vivek Buch  or Neal Lemon. Reference Docket # 18-8445



Vivodyne, Inc. is an exciting startup from Penn Bioengineering that’s creating a platform technology to answer a pressing question in biotech: how can we improve the accuracy, speed, and breadth of the modern drug development pipeline?

They are creating a groundbreaking 3D tissue culture pipeline and statistical inference engine to test drugs, biologi s, and immunotherapies directly on ultra-realistic , bioengineered human tissues. All at pharmaceutical-grade throughput.

Team Leads:

Counsel: Cooley

Seed Investor: Kairos